Drugs / LMY-920
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06340750 | Apr 2025 → Apr 2026 overdue | systemic lupus erythematosus | Luminary Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05546723 | Mar 2024 → Jul 2025 overdue | plasma cell myeloma | Luminary Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMY-920 | “In this open label, dose escalation study, up to four dose levels of autologous BAFF ligand CAR-T cells (LMY-920) will be evaluated for treatment relapsed and refractory myeloma.” NCT05546723 ↗ |
| Modality | Cell therapy | “autologous BAFF ligand CAR-T cells (LMY-920)” NCT05546723 ↗ |